Creatine comes with a convincing reputation from the gym. So when cancer treatment is taking away weight and strength, the next question feels reasonable: could the same supplement help here? We should ask it. We should also look at the cancer trials before borrowing the answer from healthy athletes.
Evidence at a glance
Studied population: adults with cancer, including people with advanced disease and appetite or weight loss. Formulation: oral creatine supplementation, with varying loading and maintenance schedules. Main finding: no established improvement in strength, lean mass or cancer-related wasting. Uncertainty: small, heterogeneous trials do not settle every rehabilitation setting.
The large direct test was negative
The 2017 Alliance N02C4 trial evaluated 263 people with incurable cancer and anorexia or weight loss. Creatine was given orally at 20 grams daily for five days, then 2 grams daily, against an identical placebo. These amounts describe the experiment, not a recommended regimen.
The main outcome was at least 10% weight gain during the first month. Only two creatine recipients and one placebo recipient reached it. Appetite, quality of life, grip strength and body composition also did not differ significantly. Adverse-event rates were similar, and there was no survival advantage.
Ten percent weight gain in a month is an ambitious target. Failure on that endpoint alone would not exclude a smaller useful effect. But the lack of a convincing strength or quality-of-life signal makes it harder to argue that the trial simply asked the wrong question.
What the 2026 review adds
A 2026 systematic review and meta-analysis, searching through April 2026, included five randomized trials and 373 patients. Pooled results did not show significant improvements in lean mass, muscle strength or physical function. The estimated lean-mass difference was 0.55 kilograms, with a wide confidence interval from −3.96 to 5.07 kilograms.
A fat-mass reduction was reported, but that is not proof of reversing wasting or improving function. Evidence certainty was low to very low. Cancer stage, dosing and accompanying exercise differed; only two studies included resistance training. Future combinations deserve study, but we cannot present those possibilities as established benefits.
Safety still needs context
Only three trials in that review reported safety outcomes, and just one specifically assessed kidney measures. An absence of a strong harm signal in small, short studies is not the same as comprehensive safety during all cancer treatments.
The NIH supplement fact sheet describes water-related weight gain and possible gastrointestinal effects with creatine. Much of its reassuring safety evidence concerns healthy people. Extra scale weight from water does not necessarily mean restored muscle. Kidney disease, dehydration and medicines affecting kidney function are reasons to review the plan with the treating team.
Bring the exact label. A creatine product mixed with stimulants or other ingredients is a different exposure from creatine alone. Do not let starting a supplement postpone assessment of progressive weight loss.
What deserves priority
The ASCO cachexia guideline supports offering dietary counseling. A dietitian and oncology team can work on intake barriers and a realistic nutrition plan. The practical target is comfort, function and adequate nourishment—not simply a heavier number on the scale.
Questions for the care team
- Is this inadequate intake, treatment toxicity, cachexia or a combination?
- How will we track muscle and function as well as weight?
- Would supervised rehabilitation and dietitian support address my needs more directly?
- Would creatine complicate kidney monitoring or add unwanted ingredients?
Creatine has not been shown to control cancer. For cancer-related wasting, the current clinical evidence does not establish a dependable benefit.
Evidence checked October 13, 2026. Educational review; research schedules and doses are not personal prescriptions. Explore the Missing Script article library and the podcast—coming soon.
